We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 18, 2021

[177Lu]Lu-PSMA-617 vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
[177Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (TheraP): A Randomised, Open-Label, Phase 2 Trial
Lancet 2021 Feb 27;397(10276)797-804, MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, DA Pattison, TH Tan, ID Kirkwood, S Ng, RJ Francis, C Gedye, NK Rutherford, A Weickhardt, AM Scott, ST Lee, EM Kwan, AA Azad, S Ramdave, AD Redfern, W Macdonald, A Guminski, E Hsiao, W Chua, P Lin, AY Zhang, MM McJannett, MR Stockler, JA Violet, SG Williams, AJ Martin, ID Davis, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading